Immunotherapy Case Study

Olink case study in cancer immunotherapy

This study, carried out in collaboration with the Massachusetts General Hospital Cancer Center, performed deep proteomic profiling together with single-cell RNAseq in a metastatic melanoma cohort during Immune Checkpoint Blockade (ICB) treatment. 
  • Initial study: >700 proteins using Olink Target 96 panels

  • Extended study: ~1500 proteins with the Olink Explore 1536 platform in an extended melanoma cohort comprising 200 patients.

  • Results demonstrate the utility of blood-based protein biomarkers to predict treatment response

Just  a few details required!

Simply type in your details and choose your country from the drop down menu to access the case study PDF.